{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:49:22Z","timestamp":1792028962344,"version":"4.4.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00134-020-06141-z","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T07:02:54Z","timestamp":1594450974000},"page":"2265-2283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Emerging pharmacological therapies for ARDS: COVID-19 and beyond"],"prefix":"10.1007","volume":"46","author":[{"given":"Shahd","family":"Horie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bairbre","family":"McNicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Rezoagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e0i","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ger","family":"Curley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"O\u2019Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Nichol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia R. M.","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Bellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1246-9573","authenticated-orcid":false,"given":"John G.","family":"Laffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"key":"6141_CR1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(67)90168-7","volume":"2","author":"DG Ashbaugh","year":"1967","unstructured":"Ashbaugh DG, Bigelow DB, Petty TL, Levine BE (1967) Acute respiratory distress in adults. Lancet 2:319\u2013323","journal-title":"Lancet"},{"key":"6141_CR2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2016.0291","volume":"315","author":"G Bellani","year":"2016","unstructured":"Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A (2016) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315:788\u2013800","journal-title":"JAMA"},{"key":"6141_CR3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S2213-2600(18)30279-0","volume":"6","author":"JG Laffey","year":"2018","unstructured":"Laffey JG, Kavanagh BP (2018) Negative trials in critical care: why most research is probably wrong. Lancet Respir Med 6:659\u2013660","journal-title":"Lancet Respir Med"},{"key":"6141_CR4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","volume":"8","author":"J Villar","year":"2020","unstructured":"Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler JA, Aguilar G, Alba F, Gonzalez-Higueras E, Conesa LA, Martin-Rodriguez C, Diaz-Dominguez FJ, Serna-Grande P, Rivas R, Ferreres J, Belda J, Capilla L, Tallet A, Anon JM, Fernandez RL, Gonzalez-Martin JM (2020) Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 8:267\u2013276","journal-title":"Lancet Respir Med"},{"key":"6141_CR5","first-page":"4665","volume":"15","author":"M Ji","year":"2018","unstructured":"Ji M, Chen T, Wang B, Chen M, Ding Q, Chen L, Fang Y, Yu X, Chen Y, Wang X, He Y, Jiang Y (2018) Effects of ulinastatin combined with mechanical ventilation on oxygen metabolism, inflammation and stress response and antioxidant capacity of ARDS. Exp Ther Med 15:4665\u20134670","journal-title":"Exp Ther Med"},{"key":"6141_CR6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2019.11825","volume":"322","author":"AA Fowler 3rd","year":"2019","unstructured":"Fowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, Fisher B, Thacker LR 2nd, Natarajan R, Brophy DF, Sculthorpe R, Nanchal R, Syed A, Sturgill J, Martin GS, Sevransky J, Kashiouris M, Hamman S, Egan KF, Hastings A, Spencer W, Tench S, Mehkri O, Bindas J, Duggal A, Graf J, Zellner S, Yanny L, McPolin C, Hollrith T, Kramer D, Ojielo C, Damm T, Cassity E, Wieliczko A, Halquist M (2019) Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA 322:1261\u20131270","journal-title":"JAMA"},{"key":"6141_CR7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1015957026924","volume":"234\u2013235","author":"SW Ryter","year":"2002","unstructured":"Ryter SW, Otterbein LE, Morse D, Choi AM (2002) Heme oxygenase\/carbon monoxide signaling pathways: regulation and functional significance. Mol Cell Biochem 234\u2013235:249\u2013263","journal-title":"Mol Cell Biochem"},{"key":"6141_CR8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12931-015-0274-7","volume":"16","author":"N Jahn","year":"2015","unstructured":"Jahn N, Lamberts RR, Busch CJ, Voelker MT, Busch T, Koel-Simmelink MJ, Teunissen CE, Oswald DD, Loer SA, Kaisers UX, Weimann J (2015) Inhaled carbon monoxide protects time-dependently from loss of hypoxic pulmonary vasoconstriction in endotoxemic mice. Respir Res 16:119","journal-title":"Respir Res"},{"issue":"23","key":"6141_CR9","doi-asserted-by":"crossref","first-page":"e124039","DOI":"10.1172\/jci.insight.124039","volume":"3","author":"LE Fredenburgh","year":"2018","unstructured":"Fredenburgh LE, Perrella MA, Barragan-Bradford D, Hess DR, Peters E, Welty-Wolf KE, Kraft BD, Harris RS, Maurer R, Nakahira K, Oromendia C, Davies JD, Higuera A, Schiffer KT, Englert JA, Dieffenbach PB, Berlin DA, Lagambina S, Bouthot M, Sullivan AI, Nuccio PF, Kone MT, Malik MJ, Porras MAP, Finkelsztein E, Winkler T, Hurwitz S, Serhan CN, Piantadosi CA, Baron RM, Thompson BT, Choi AM (2018) A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS. JCI Insight 3(23):e124039","journal-title":"JCI Insight"},{"key":"6141_CR10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/thoraxjnl-2015-206813","volume":"70","author":"J Devaney","year":"2015","unstructured":"Devaney J, Horie S, Masterson C, Elliman S, Barry F, O'Brien T, Curley GF, O'Toole D, Laffey JG (2015) Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax 70:625\u2013635","journal-title":"Thorax"},{"key":"6141_CR11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40635-020-0295-5","volume":"8","author":"S Horie","year":"2020","unstructured":"Horie S, Gaynard S, Murphy M, Barry F, Scully M, O'Toole D, Laffey JG (2020) Cytokine pre-activation of cryopreserved xenogeneic-free human mesenchymal stromal cells enhances resolution and repair following ventilator-induced lung injury potentially via a KGF-dependent mechanism. Intensive Care Med Exp 8:8","journal-title":"Intensive Care Med Exp"},{"key":"6141_CR12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","volume":"3","author":"JG Wilson","year":"2014","unstructured":"Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA (2014) Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3:24\u201332","journal-title":"Lancet Respir Med"},{"key":"6141_CR13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","volume":"7","author":"MA Matthay","year":"2018","unstructured":"Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK, Donahoe MP, McVerry BJ, Ortiz LA, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD (2018) Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med 7:154\u2013162","journal-title":"Lancet Respir Med"},{"key":"6141_CR14","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1097\/CCM.0000000000004285","volume":"48","author":"HK Yip","year":"2020","unstructured":"Yip HK, Fang WF, Li YC, Lee FY, Lee CH, Pei SN, Ma MC, Chen KH, Sung PH, Lee MS (2020) Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome. Crit Care Med 48:e391\u2013e399","journal-title":"Crit Care Med"},{"key":"6141_CR15","unstructured":"Jacono F, Bannard-Smith J, Brealey D, Meyer N, Thickett D, Young D, Bentley A, McVerry B, Wunderink RG, Doerschug KC, Summers C, Rojas M, Jenkins ED, Ting A (2019) Primary analysis of a phase 1\/2 study to assess MultiStem\u00c2\u00ae cell therapy, a regenerative advanced therapy medicinal product (ATMP), in acute respiratory distress syndrome (MUST-ARDS)B14 late breaking clinical trials, pp A7353\u2013A7353"},{"key":"6141_CR16","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/CCM.0000000000001132","volume":"43","author":"JD Christie","year":"2015","unstructured":"Christie JD, Vaslef S, Chang PK, May AK, Gunn SR, Yang S, Hardes K, Kahl L, Powley WM, Lipson DA, Bayliffe AI, Lazaar AL (2015) A Randomized dose-escalation study of the safety and anti-inflammatory activity of the p38 mitogen-activated protein kinase inhibitor dilmapimod in severe trauma subjects at risk for acute respiratory distress syndrome. Crit Care Med 43:1859\u20131869","journal-title":"Crit Care Med"},{"key":"6141_CR17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/thoraxjnl-2017-210305","volume":"73","author":"A Proudfoot","year":"2018","unstructured":"Proudfoot A, Bayliffe A, O'Kane CM, Wright T, Serone A, Bareille PJ, Brown V, Hamid UI, Chen Y, Wilson R, Cordy J, Morley P, de Wildt R, Elborn S, Hind M, Chilvers ER, Griffiths M, Summers C, McAuley DF (2018) Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury. Thorax 73:723\u2013730","journal-title":"Thorax"},{"key":"6141_CR18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13054-017-1795-x","volume":"21","author":"K Krenn","year":"2017","unstructured":"Krenn K, Lucas R, Croize A, Boehme S, Klein KU, Hermann R, Markstaller K, Ullrich R (2017) Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial. Crit Care 21:194","journal-title":"Crit Care"},{"key":"6141_CR19","doi-asserted-by":"crossref","first-page":"R10","DOI":"10.1186\/cc11934","volume":"17","author":"LB Ware","year":"2013","unstructured":"Ware LB, Magarik JA, Wickersham N, Cunningham G, Rice TW, Christman BW, Wheeler AP, Bernard GR, Summar ML (2013) Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis. Crit Care 17:R10","journal-title":"Crit Care"},{"key":"6141_CR20","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1097\/CCM.0b013e31828a6688","volume":"41","author":"N Klein","year":"2013","unstructured":"Klein N, Gembardt F, Supe S, Kaestle SM, Nickles H, Erfinanda L, Lei X, Yin J, Wang L, Mertens M, Szaszi K, Walther T, Kuebler WM (2013) Angiotensin-(1\u20137) protects from experimental acute lung injury. Crit Care Med 41:e334\u2013e343","journal-title":"Crit Care Med"},{"key":"6141_CR21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40635-015-0044-3","volume":"3","author":"V Zambelli","year":"2015","unstructured":"Zambelli V, Bellani G, Borsa R, Pozzi F, Grassi A, Scanziani M, Castiglioni V, Masson S, Decio A, Laffey JG, Latini R, Pesenti A (2015) Angiotensin-(1\u20137) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute respiratory distress syndrome. Intensive Care Med Exp 3:44","journal-title":"Intensive Care Med Exp"},{"key":"6141_CR22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","volume":"21","author":"A Khan","year":"2017","unstructured":"Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe AI, Lazaar AL (2017) A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care 21:234","journal-title":"Crit Care"},{"key":"6141_CR23","doi-asserted-by":"crossref","first-page":"L1035","DOI":"10.1152\/ajplung.00214.2009","volume":"297","author":"JA Bastarache","year":"2009","unstructured":"Bastarache JA, Fremont RD, Kropski JA, Bossert FR, Ware LB (2009) Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 297:L1035\u20131041","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"6141_CR24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2466-12-5","volume":"12","author":"PE Morris","year":"2012","unstructured":"Morris PE, Steingrub JS, Huang BY, Tang S, Liu PM, Rhode PR, Wong HC (2012) A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome. BMC Pulm Med 12:5","journal-title":"BMC Pulm Med"},{"key":"6141_CR25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jth.14685","volume":"18","author":"M Camprubi-Rimblas","year":"2019","unstructured":"Camprubi-Rimblas M, Tantinya N, Guillamat-Prats R, Bringue J, Puig F, Gomez MN, Blanch L, Artigas A (2019) Effects of nebulized antithrombin and heparin on inflammatory and coagulation alterations in an acute lung injury model in rats. J Thromb Haemost 18:571\u2013583","journal-title":"J Thromb Haemost"},{"key":"6141_CR26","doi-asserted-by":"crossref","first-page":"R180","DOI":"10.1186\/cc9286","volume":"14","author":"B Dixon","year":"2010","unstructured":"Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ (2010) Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 14:R180","journal-title":"Crit Care"},{"key":"6141_CR27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0310057X1604400106","volume":"44","author":"B Dixon","year":"2015","unstructured":"Dixon B, Smith R, Santamaria JD, Orford NR, Wakefield BJ, Ives K, McKenzie R, Zhang B, Yap CH (2015) A trial of nebulised heparin to limit lung injury following cardiac surgery. Anaesth Intensive Care 44:28\u201333","journal-title":"Anaesth Intensive Care"},{"key":"6141_CR28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.jvca.2019.05.035","volume":"34","author":"A Abdelaal Ahmed Mahmoud","year":"2019","unstructured":"Abdelaal Ahmed Mahmoud A, Mahmoud HE, Mahran MA, Khaled M (2019) Streptokinase versus unfractionated heparin nebulization in patients with severe acute respiratory distress syndrome (ARDS): a randomized controlled trial with observational controls. J Cardiothorac Vasc Anesth 34:436\u2013443","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"6141_CR29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/thoraxjnl-2012-202536","volume":"68","author":"A Kerrin","year":"2013","unstructured":"Kerrin A, Weldon S, Chung AH, Craig T, Simpson AJ, O'Kane CM, McAuley DF, Taggart CC (2013) Proteolytic cleavage of elafin by 20S proteasome may contribute to inflammation in acute lung injury. Thorax 68:315\u2013321","journal-title":"Thorax"},{"key":"6141_CR30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/mt.2014.162","volume":"23","author":"DM Small","year":"2015","unstructured":"Small DM, Zani ML, Quinn DJ, Dallet-Choisy S, Glasgow AM, O'Kane C, McAuley DF, McNally P, Weldon S, Moreau T, Taggart CC (2015) A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation. Mol Ther 23:24\u201331","journal-title":"Mol Ther"},{"key":"6141_CR31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/SHK.0000000000000845","volume":"48","author":"T Wang","year":"2017","unstructured":"Wang T, Zhu Z, Liu Z, Yi L, Yang Z, Bian W, Chen W, Wang S, Li G, Li A, Martin GS, Zhu X (2017) Plasma neutrophil elastase and elafin as prognostic biomarker for acute respiratory distress syndrome: a multicenter survival and longitudinal prospective observation study. Shock 48:168\u2013174","journal-title":"Shock"},{"key":"6141_CR32","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1086\/377238","volume":"188","author":"C Greene","year":"2003","unstructured":"Greene C, Taggart C, Lowe G, Gallagher P, McElvaney N, O\u2019Neill S (2003) Local impairment of anti-neutrophil elastase capacity in community-acquired pneumonia. J Infect Dis 188:769\u2013776","journal-title":"J Infect Dis"},{"key":"6141_CR33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01902148.2019.1642968","volume":"45","author":"X Wang","year":"2019","unstructured":"Wang X, Gong J, Zhu J, Jin Z, Gao W (2019) Alpha 1-antitrypsin for treating ventilator-associated lung injury in acute respiratory distress syndrome rats. Exp Lung Res 45:209\u2013219","journal-title":"Exp Lung Res"},{"key":"6141_CR34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40635-019-0240-7","volume":"7","author":"J Juschten","year":"2019","unstructured":"Juschten J, Ingelse SA, Maas MAW, Girbes ARJ, Juffermans NP, Schultz MJ, Tuinman PR (2019) Antithrombin plus alpha-1 protease inhibitor does not affect coagulation and inflammation in two murine models of acute lung injury. Intensive Care Med Exp 7:36","journal-title":"Intensive Care Med Exp"},{"key":"6141_CR35","doi-asserted-by":"crossref","first-page":"L1294","DOI":"10.1152\/ajplung.00031.2015","volume":"309","author":"AN Rizzo","year":"2015","unstructured":"Rizzo AN, Sammani S, Esquinca AE, Jacobson JR, Garcia JG, Letsiou E, Dudek SM (2015) Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 309:L1294\u20131304","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"6141_CR36","doi-asserted-by":"crossref","unstructured":"Stephens RS, Johnston L, Servinsky L, Kim BS, Damarla M, (2015) The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice. Physiol Rep 3(11)","DOI":"10.14814\/phy2.12589"},{"key":"6141_CR37","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1089\/hum.2008.169","volume":"20","author":"M Watanabe","year":"2009","unstructured":"Watanabe M, Boyer JL, Crystal RG (2009) Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema. Hum Gene Ther 20:598\u2013610","journal-title":"Hum Gene Ther"},{"key":"6141_CR38","doi-asserted-by":"crossref","unstructured":"Ranieri VM, Pettila V, Karvonen MK, Jalkanen J, Nightingale P, Brealey D, Mancebo J, Ferrer R, Mercat A, Patroniti N, Quintel M, Vincent JL, Okkonen M, Meziani F, Bellani G, MacCallum N, Creteur J, Kluge S, Artigas-Raventos A, Maksimow M, Piippo I, Elima K, Jalkanen S, Jalkanen M, Bellingan G; Group IS (2020) Effect of intravenous interferon beta-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial. JAMA https:doi.org\/10.1001\/jama.2019.22525","DOI":"10.1001\/jama.2019.22525"},{"key":"6141_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2019.07.009","author":"B Liu","year":"2019","unstructured":"Liu B, Bao L, Wang L, Li F, Wen M, Li H, Deng W, Zhang X, Cao B (2019) Anti-IFN-gamma therapy alleviates acute lung injury induced by severe influenza A (H1N1) pdm09 infection in mice. J Microbiol Immunol Infect. https:\/\/doi.org\/10.1016\/j.jmii.2019.07.009","journal-title":"J Microbiol Immunol Infect"},{"key":"6141_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.04.035","author":"CGK Ziegler","year":"2020","unstructured":"Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, Feldman J, Muus C, Wadsworth MH 2nd, Kazer SW, Hughes TK, Doran B, Gatter GJ, Vukovic M, Taliaferro F, Mead BE, Guo Z, Wang JP, Gras D, Plaisant M, Ansari M, Angelidis I, Adler H, Sucre JMS, Taylor CJ, Lin B, Waghray A, Mitsialis V, Dwyer DF, Buchheit KM, Boyce JA, Barrett NA, Laidlaw TM, Carroll SL, Colonna L, Tkachev V, Peterson CW, Yu A, Zheng HB, Gideon HP, Winchell CG, Lin PL, Bingle CD, Snapper SB, Kropski JA, Theis FJ, Schiller HB, Zaragosi LE, Barbry P, Leslie A, Kiem HP, Flynn JL, Fortune SM, Berger B, Finberg RW, Kean LS, Garber M, Schmidt AG, Lingwood D, Shalek AK, Ordovas-Montanes J (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. https:\/\/doi.org\/10.1016\/j.cell.2020.04.035","journal-title":"Cell"},{"key":"6141_CR41","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.4049\/jimmunol.1400368","volume":"192","author":"JJ Grailer","year":"2015","unstructured":"Grailer JJ, Canning BA, Kalbitz M, Haggadone MD, Dhond RM, Andjelkovic AV, Zetoune FS, Ward PA (2015) Critical role for the NLRP3 inflammasome during acute lung injury. J Immunol 192:5974\u20135983","journal-title":"J Immunol"},{"key":"6141_CR42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.molimm.2018.05.003","volume":"99","author":"Y Li","year":"2018","unstructured":"Li Y, Li H, Liu S, Pan P, Su X, Tan H, Wu D, Zhang L, Song C, Dai M, Li Q, Mao Z, Long Y, Hu Y, Hu C (2018) Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. Mol Immunol 99:134\u2013144","journal-title":"Mol Immunol"},{"key":"6141_CR43","doi-asserted-by":"crossref","unstructured":"Bode C, Peukert K, Schewe J-C, Putensen C, Latz E, Steinhagen F, (2019) Tetracycline alleviates acute lung injury by inhibition of NLRP3 inflammasome. Eur Respir J 54:PA2175","DOI":"10.1183\/13993003.congress-2019.PA2175"},{"key":"6141_CR44","doi-asserted-by":"crossref","first-page":"L817","DOI":"10.1152\/ajplung.00254.2014","volume":"307","author":"RE Morty","year":"2014","unstructured":"Morty RE, Kuebler WM (2014) TRPV4: an exciting new target to promote alveolocapillary barrier function. Am J Physiol Lung Cell Mol Physiol 307:L817\u2013821","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"6141_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00413","author":"L Michalick","year":"2020","unstructured":"Michalick L, Kuebler WM (2020) TRPV4\u2014a missing link between mechanosensation and immunity. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.00413","journal-title":"Front Immunol"},{"key":"6141_CR46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3389\/fimmu.2017.00503","volume":"8","author":"RG Scheraga","year":"2017","unstructured":"Scheraga RG, Southern BD, Grove LM, Olman MA (2017) The role of transient receptor potential vanilloid 4 in pulmonary inflammatory diseases. Front Immunol 8:503","journal-title":"Front Immunol"},{"key":"6141_CR47","doi-asserted-by":"crossref","first-page":"L353","DOI":"10.1152\/ajplung.00315.2009","volume":"299","author":"K Hamanaka","year":"2010","unstructured":"Hamanaka K, Jian M-Y, Townsley MI, King JA, Liedtke W, Weber DS, Eyal FG, Clapp MM, Parker JC (2010) TRPV4 channels augment macrophage activation and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 299:L353\u2013L362","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"6141_CR48","doi-asserted-by":"crossref","first-page":"L158","DOI":"10.1152\/ajplung.00065.2014","volume":"307","author":"S Balakrishna","year":"2014","unstructured":"Balakrishna S, Song W, Achanta S, Doran SF, Liu B, Kaelberer MM, Yu Z, Sui A, Cheung M, Leishman E, Eidam HS, Ye G, Willette RN, Thorneloe KS, Bradshaw HB, Matalon S, Jordt SE (2014) TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 307:L158\u2013172","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"6141_CR49","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.4049\/jimmunol.1901033","volume":"204","author":"RG Scheraga","year":"2020","unstructured":"Scheraga RG, Abraham S, Grove LM, Southern BD, Crish JF, Perelas A, McDonald C, Asosingh K, Hasday JD, Olman MA (2020) TRPV4 protects the lung from bacterial Pneumonia via MAPK molecular pathway switching. J Immunol 204:1310\u20131321","journal-title":"J Immunol"},{"key":"6141_CR50","doi-asserted-by":"crossref","first-page":"L259","DOI":"10.1152\/ajplung.00395.2011","volume":"303","author":"GF Hans","year":"2012","unstructured":"Hans GF, Stephanie RK, David AL, Michael AM, Mark AS (2012) The adenosine 2A receptor agonist GW328267C improves lung function after acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol 303:L259\u2013L271","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"6141_CR51","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1097\/CCM.0b013e3181a55273","volume":"37","author":"CM Chen","year":"2009","unstructured":"Chen CM, Penuelas O, Quinn K, Cheng KC, Li CF, Zhang H, Slutsky AS (2009) Protective effects of adenosine A2A receptor agonist in ventilator-induced lung injury in rats. Crit Care Med 37:2235\u20132241","journal-title":"Crit Care Med"},{"key":"6141_CR52","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1038\/s41598-018-20994-x","volume":"8","author":"M Jabaudon","year":"2018","unstructured":"Jabaudon M, Berthelin P, Pranal T, Roszyk L, Godet T, Faure JS, Chabanne R, Eisenmann N, Lautrette A, Belville C, Blondonnet R, Cayot S, Gillart T, Pascal J, Skrzypczak Y, Souweine B, Blanchon L, Sapin V, Pereira B, Constantin JM (2018) Receptor for advanced glycation end-products and ARDS prediction: a multicentre observational study. Sci Rep 8:2603","journal-title":"Sci Rep"},{"key":"6141_CR53","doi-asserted-by":"crossref","first-page":"7208","DOI":"10.1038\/s41598-017-07638-2","volume":"7","author":"R Blondonnet","year":"2017","unstructured":"Blondonnet R, Audard J, Belville C, Clairefond G, Lutz J, Bouvier D, Roszyk L, Gross C, Lavergne M, Fournet M, Blanchon L, Vachias C, Damon-Soubeyrand C, Sapin V, Constantin JM, Jabaudon M (2017) RAGE inhibition reduces acute lung injury in mice. Sci Rep 7:7208","journal-title":"Sci Rep"},{"key":"6141_CR54","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1038\/s41598-019-45798-5","volume":"9","author":"J Audard","year":"2019","unstructured":"Audard J, Godet T, Blondonnet R, Joffredo JB, Paquette B, Belville C, Lavergne M, Gross C, Pasteur J, Bouvier D, Blanchon L, Sapin V, Pereira B, Constantin JM, Jabaudon M (2019) Inhibition of the receptor for advanced glycation end-products in acute respiratory distress syndrome: a randomised laboratory trial in piglets. Sci Rep 9:9227","journal-title":"Sci Rep"},{"key":"6141_CR55","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123013","author":"KE Remy","year":"2018","unstructured":"Remy KE, Cortes-Puch I, Solomon SB, Sun J, Pockros BM, Feng J, Lertora JJ, Hantgan RR, Liu X, Perlegas A, Warren HS, Gladwin MT, Kim-Shapiro DB, Klein HG, Natanson C (2018) Haptoglobin improves shock, lung injury, and survival in canine pneumonia. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.123013","journal-title":"JCI Insight"},{"key":"6141_CR56","doi-asserted-by":"crossref","first-page":"L402","DOI":"10.1152\/ajplung.00115.2002","volume":"284","author":"F Yang","year":"2003","unstructured":"Yang F, Haile DJ, Berger FG, Herbert DC, Van Beveren E, Ghio AJ (2003) Haptoglobin reduces lung injury associated with exposure to blood. Am J Physiol Lung Cell Mol Physiol 284:L402\u2013409","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"6141_CR57","doi-asserted-by":"crossref","unstructured":"Zheng S, D'Souza VK, Bartis D, Dancer RC, Parekh D, Naidu B, Gao-Smith F, Wang Q, Jin S, Lian Q, Thickett DR (2016) Lipoxin A4 promotes lung epithelial repair whilst inhibiting fibroblast proliferation. ERJ Open Res 2(3)","DOI":"10.1183\/23120541.00079-2015"},{"key":"6141_CR58","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12931-019-1158-z","volume":"20","author":"JX Yang","year":"2019","unstructured":"Yang JX, Li M, Chen XO, Lian QQ, Wang Q, Gao F, Jin SW, Zheng SX (2019) Lipoxin A4 ameliorates lipopolysaccharide-induced lung injury through stimulating epithelial proliferation, reducing epithelial cell apoptosis and inhibits epithelial-mesenchymal transition. Respir Res 20:192","journal-title":"Respir Res"},{"key":"6141_CR59","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381\u2013385","journal-title":"Nature"},{"key":"6141_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653","author":"TP Sheahan","year":"2017","unstructured":"Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aal3653","journal-title":"Sci Transl Med"},{"key":"6141_CR61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269\u2013271","journal-title":"Cell Res"},{"key":"6141_CR62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016","author":"J Grein","year":"2020","unstructured":"Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2007016","journal-title":"N Engl J Med"},{"key":"6141_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(20)31022-9","journal-title":"Lancet"},{"key":"6141_CR64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, Members A-SG (2020) Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"6141_CR65","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449\u2013463","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"6141_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007","author":"Q Cai","year":"2020","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. https:\/\/doi.org\/10.1016\/j.eng.2020.03.007","journal-title":"Engineering"},{"key":"6141_CR67","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:1787\u20131799","journal-title":"N Engl J Med"},{"key":"6141_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31042-4","author":"IF-N Hung","year":"2020","unstructured":"Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, Ng Y-Y, Lo J, Chan J, Tam AR (2020) Triple combination of interferon beta-1b, lopinavir\/ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(20)31042-4","journal-title":"Lancet"},{"key":"6141_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.060","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, Jianchun XY (2020) Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19. J Infect. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.060","journal-title":"J Infect"},{"key":"6141_CR70","doi-asserted-by":"crossref","unstructured":"Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Ju L, Zhang J, Wang X, (2020) Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv: 2020.2003.2017.20037432","DOI":"10.1101\/2020.03.17.20037432"},{"key":"6141_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa114","author":"D Zhou","year":"2020","unstructured":"Zhou D, Dai SM, Tong Q (2020) COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. https:\/\/doi.org\/10.1093\/jac\/dkaa114","journal-title":"J Antimicrob Chemother"},{"key":"6141_CR72","first-page":"55","volume":"24","author":"BE van den Borne","year":"1997","unstructured":"van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL (1997) Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 24:55\u201360","journal-title":"J Rheumatol"},{"key":"6141_CR73","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/cr.2012.165","volume":"23","author":"Y Yan","year":"2013","unstructured":"Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, Jin N, Jiang C (2013) Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 23:300\u2013302","journal-title":"Cell Res"},{"key":"6141_CR74","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949","DOI":"10.1101\/2020.03.16.20037135"},{"key":"6141_CR75","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1834","author":"NJ Mercuro","year":"2020","unstructured":"Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold HS (2020) Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2020.1834","journal-title":"JAMA Cardiol"},{"key":"6141_CR76","doi-asserted-by":"crossref","unstructured":"Borba MGS, Val FFA, Sampaio VS, Alexandre MAAJ, Melo GC, Brito M, Mour\u00e3o MPG, Brito-Sousa JD, Ba\u00e3a-da-Silva D, Guerra MVF (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 3: e208857\u2013e208857","DOI":"10.1001\/jamanetworkopen.2020.8857"},{"key":"6141_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31180-6","author":"MR Mehra","year":"2020","unstructured":"Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(20)31180-6","journal-title":"Lancet"},{"key":"6141_CR78","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S, (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271\u2013280e8","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"6141_CR79","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395:e30\u2013e31","journal-title":"Lancet"},{"key":"6141_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.017","author":"F Cantini","year":"2020","unstructured":"Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D (2020) Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. https:\/\/doi.org\/10.1016\/j.jinf.2020.04.017","journal-title":"J Infect"},{"key":"6141_CR81","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","volume":"144","author":"IFN Hung","year":"2013","unstructured":"Hung IFN, To KKW, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu R, Lai KY, Lau CCY, Liu SH, Chan KH, Lin CK, Yuen KY (2013) Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144:464\u2013473","journal-title":"Chest"},{"key":"6141_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783","author":"C Shen","year":"2020","unstructured":"Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L (2020) Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.4783","journal-title":"JAMA"},{"key":"6141_CR83","doi-asserted-by":"publisher","unstructured":"Joyner M, Wright RS, Fairweather D, Senefeld J, Bruno K, Klassen S, Carter R, Klompas A, Wiggins C, Shepherd JRA, Rea R, Whelan E, Clayburn A, Spiegel M, Johnson P, Lesser E, Baker S, Larson K, Ripoll Sanz J, Andersen K, Hodge D, Kunze K, Buras M, Vogt M, Herasevich V, Dennis J, Regimbal R, Bauer P, Blair J, van Buskirk C, Winters J, Stubbs J, Paneth N, Casadevall A (2020) Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 140200. https:\/\/doi.org\/10.1172\/JCI140200","DOI":"10.1172\/JCI140200"},{"key":"6141_CR84","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","volume":"395","author":"L Shang","year":"2020","unstructured":"Shang L, Zhao J, Hu Y, Du R, Cao B (2020) On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 395:683\u2013684","journal-title":"Lancet"},{"key":"6141_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00170","author":"N Veronese","year":"2020","unstructured":"Veronese N, Demurtas J, Yang L, Tonelli R, Barbagallo M, Lopalco P, Lagolio E, Celotto S, Pizzol D, Zou L, Tully MA, Ilie PC, Trott M, L\u00e3pez-S\u00e3nchez GF, Smith L (2020) Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med. https:\/\/doi.org\/10.3389\/fmed.2020.00170","journal-title":"Front Med"},{"key":"6141_CR86","doi-asserted-by":"crossref","first-page":"e0111","DOI":"10.1097\/CCE.0000000000000111","volume":"2","author":"V Js","year":"2020","unstructured":"Js V, Confalonieri M, Pastores SM, Meduri GU (2020) Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019. Crit Care Explor 2:e0111","journal-title":"Crit Care Explor"},{"key":"6141_CR87","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","volume":"197","author":"YM Arabi","year":"2018","unstructured":"Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A, Almotairi A, Al Khatib K, Alraddadi B, Shalhoub S, Abdulmomen A, Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Balkhy HH, Al Harthy A, Deeb AM, Al Mutairi H, Al-Dawood A, Merson L, Hayden FG, Fowler RA, Saudi Critical Care Trial G (2018) Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 197:757\u2013767","journal-title":"Am J Respir Crit Care Med"},{"key":"6141_CR88","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-020-0158-2","volume":"5","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang W, He Q et al (2020) A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Sig Transduct Target Ther 5:57. https:\/\/doi.org\/10.1038\/s41392-020-0158-2","journal-title":"Sig Transduct Target Ther"},{"key":"6141_CR89","doi-asserted-by":"crossref","unstructured":"Wu C, Chen X, Cai Y, Xia Ja, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y, (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"6141_CR90","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.intimp.2010.04.008","volume":"10","author":"V Kumar","year":"2010","unstructured":"Kumar V, Harjai K, Chhibber S (2010) Thalidomide treatment modulates macrophage pro-inflammatory function and cytokine levels in Klebsiella pneumoniae B5055 induced pneumonia in BALB\/c mice. Int Immunopharmacol 10:777\u2013783","journal-title":"Int Immunopharmacol"},{"key":"6141_CR91","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s10753-014-9943-9","volume":"37","author":"H Zhu","year":"2014","unstructured":"Zhu H, Shi X, Ju D, Huang H, Wei W, Dong X (2014) Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice. Inflammation 37:2091\u20132098","journal-title":"Inflammation"},{"key":"6141_CR92","doi-asserted-by":"crossref","first-page":"104791","DOI":"10.1016\/j.antiviral.2020.104791","volume":"178","author":"E Sallard","year":"2020","unstructured":"Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N (2020) Type 1 interferons as a potential treatment against COVID-19. Antiviral Res 178:104791","journal-title":"Antiviral Res"},{"key":"6141_CR93","doi-asserted-by":"crossref","first-page":"e792","DOI":"10.1016\/j.ijid.2013.07.002","volume":"17","author":"H Momattin","year":"2013","unstructured":"Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA (2013) Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)\u2013possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 17:e792\u2013798","journal-title":"Int J Infect Dis"},{"key":"6141_CR94","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC120.013788","author":"KG Lokugamage","year":"2020","unstructured":"Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R, Menachery VD (2020) SARS-CoV-2 is sensitive to type I interferon pretreatment. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.AC120.013788","journal-title":"J Biol Chem"},{"key":"6141_CR95","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","volume":"11","author":"Z Leng","year":"2020","unstructured":"Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-Hughes G, Caruso C, Jin K, Zhao RC (2020) Transplantation of ACE2(\u2212) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 11:216\u2013228","journal-title":"Aging Dis"},{"key":"6141_CR96","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497\u2013506","journal-title":"Lancet"},{"key":"6141_CR97","doi-asserted-by":"crossref","first-page":"e7596","DOI":"10.1097\/MD.0000000000007596","volume":"96","author":"A Masui-Ito","year":"2017","unstructured":"Masui-Ito A, Okamoto R, Ikejiri K, Fujimoto M, Tanimura M, Nakamori S, Murata T, Ishikawa E, Yamada N, Imai H, Ito M (2017) Tocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset still disease: case report and review of literature. Medicine (Baltimore) 96:e7596","journal-title":"Medicine (Baltimore)"},{"key":"6141_CR98","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/RHU.0000000000000374","volume":"22","author":"CD Morrondo","year":"2016","unstructured":"Morrondo CD, Zarza LP, Gil JG, Pinto Tasende JA, Diez PD, Lopez JM (2016) Benefit of tocilizumab therapy for adult-onset still disease complicated with acute respiratory distress syndrome. J Clin Rheumatol 22:291\u2013293","journal-title":"J Clin Rheumatol"},{"issue":"20","key":"6141_CR99","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 117(20):10970\u201310975. https:\/\/doi.org\/10.1073\/pnas.2005615117","journal-title":"Proc Natl Acad Sci USA"},{"key":"6141_CR100","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","volume":"271","author":"CJ Fisher Jr","year":"1994","unstructured":"Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL et al (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836\u20131843","journal-title":"JAMA"},{"key":"6141_CR101","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00003246-199601000-00010","volume":"24","author":"WA Knaus","year":"1996","unstructured":"Knaus WA, Harrell FE Jr, LaBrecque JF, Wagner DP, Pribble JP, Draper EA, Fisher CJ Jr, Soll L (1996) Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med 24:46\u201356","journal-title":"Crit Care Med"},{"key":"6141_CR102","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","volume":"25","author":"SM Opal","year":"1997","unstructured":"Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25:1115\u20131124","journal-title":"Crit Care Med"},{"key":"6141_CR103","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","volume":"44","author":"B Shakoory","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM (2016) Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 44:275\u2013281","journal-title":"Crit Care Med"},{"key":"6141_CR104","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18:1094\u20131099","journal-title":"J Thromb Haemost"},{"key":"6141_CR105","doi-asserted-by":"crossref","unstructured":"Dixon B, Smith R, Artigas A, Laffey J, McNicholas B, Schmidt E, Nunes Q, Skidmore MA, Andrade de Lome M, Moran J, Van Haren F, Doig G, Gupta S, Ghosh A, Said S, Santamaria J (2020) Can nebulised heparin reduce time to extubation in SARS CoV 2 the CHARTER study protocol. medRxiv:2020.2004.2028.20082552","DOI":"10.1101\/2020.04.28.20082552"},{"key":"6141_CR106","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/MCC.0000000000000641","volume":"25","author":"M Shankar-Hari","year":"2019","unstructured":"Shankar-Hari M, Rubenfeld GD (2019) Population enrichment for critical care trials: phenotypes and differential outcomes. Curr Opin Crit Care 25:489\u2013497","journal-title":"Curr Opin Crit Care"},{"key":"6141_CR107","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","volume":"6","author":"CS Calfee","year":"2018","unstructured":"Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF (2018) Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 6:691\u2013698","journal-title":"Lancet Respir Med"},{"key":"6141_CR108","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S2213-2600(19)30138-9","volume":"7","author":"JM Constantin","year":"2019","unstructured":"Constantin JM, Jabaudon M, Lefrant JY, Jaber S, Quenot JP, Langeron O, Ferrandiere M, Grelon F, Seguin P, Ichai C, Veber B, Souweine B, Uberti T, Lasocki S, Legay F, Leone M, Eisenmann N, Dahyot-Fizelier C, Dupont H, Asehnoune K, Sossou A, Chanques G, Muller L, Bazin JE, Monsel A, Borao L, Garcier JM, Rouby JJ, Pereira B, Futier E (2019) Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. Lancet Respir Med 7:870\u2013880","journal-title":"Lancet Respir Med"},{"key":"6141_CR109","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/thoraxjnl-2016-209719","volume":"72","author":"LD Bos","year":"2017","unstructured":"Bos LD, Schouten LR, van Vught LA, Wiewel MA, Ong DSY, Cremer O, Artigas A, Martin-Loeches I, Hoogendijk AJ, van der Poll T, Horn J, Juffermans N, Calfee CS, Schultz MJ (2017) Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax 72:876\u2013883","journal-title":"Thorax"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-020-06141-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-020-06141-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-020-06141-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T23:08:17Z","timestamp":1625958497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-020-06141-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":109,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6141"],"URL":"https:\/\/doi.org\/10.1007\/s00134-020-06141-z","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}